EURONEXT-PAR$SNY
Sanofi · Q2 2026 earnings
Q2 2026 earnings · · Investor relations
Briefing
Sanofi reported strong Q2 2026 results with double-digit sales growth and upgraded full-year guidance.
Sanofi delivered Q2 2026 net sales of €11.6 billion, up 17.8% at constant exchange rates, driven by Dupixent and pharma launches. Business EPS rose 33.3% to €2.09, while IFRS net income was €343 million. The company upgraded its 2026 guidance to around 10% sales growth at CER with business EPS growing slightly faster.
- Q2 net sales €11,597 million (+17.8% CER), with Dupixent at €5.2 billion (+37.6%) and pharma launches at €1.3 billion (+48.3%).
- Business EPS €2.09 (+33.3% CER); IFRS EPS €0.29; business net income €2,501 million.
- Free cash flow €2,670 million (+86.8%); R&D expenses €2.2 billion (+17.9%).
- 2026 guidance upgraded: sales ~10% at CER, business EPS growing slightly faster than sales.
Headline financials
Revenue & EPS history
Sanofi · Revenue · Quarterly
€13.3B
Revenue by segment
Sanofi · €7.56B total across 3 segments · Q2 2026
- Dupixent€5.15B—68.2%
- Pharma launches€1.31B—17.3%
- Vaccines€1.1B—14.6%
Forward guidance
2026 sales expected to grow around 10% at CER; business EPS to grow slightly faster than sales at CER.
Tailwinds
- Strong H1 performance supports upgraded outlook.
- Dupixent and launches driving growth.
- Pipeline progress with approvals and positive readouts.
Headwinds
- Anticipated normalization of growth in H2.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports
-0.5%
Avg return
Earnings day
-0.3%
Avg return
5 days after
+1.5%
Avg return
30 days after
44%
17 / 39 earnings
Positive
+6.1%
Q4 2016
Best reaction
-15.9%
Q3 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2026 | — | — | — | |
| Q1 2026 | -1.0% | -2.0% | +64.0% | |
| Q3 2025 | +2.2% | +1.6% | -1.5% | |
| H1 2025 | -6.4% | -2.9% | +0.5% | |
| Q2 2024 | +2.3% | +1.0% | +9.8% | |
| Q4 2023 | -5.4% | -5.7% | -5.2% | |
| Q3 2023 | -15.9% | -13.1% | -11.5% | |
| Q2 2023 | -0.3% | -3.8% | -0.2% | |
| Q1 2023 | -4.6% | -5.1% | -6.6% | |
| Q4 2022 | -2.9% | +1.0% | +1.1% | |
| Q3 2022 | +4.0% | +3.3% | +9.2% | |
| Q2 2022 | -2.4% | -4.2% | -19.8% | |
| Q1 2022 | -3.8% | -1.7% | +1.5% | |
| Q4 2021 | +1.1% | +2.3% | -7.6% | |
| Q2 2021 | -1.0% | +4.8% | -2.6% | |
| Q3 2021 | +1.7% | +4.8% | -2.6% | |
| Q1 2021 | +2.2% | -1.1% | -0.4% | |
| Q4 2020 | +3.2% | +2.0% | -1.1% | |
| Q2 2020 | +1.3% | +3.1% | +10.8% | |
| Q3 2020 | -1.8% | +3.1% | +10.8% | |
| Q1 2020 | +4.7% | -2.6% | -2.5% | |
| Q4 2019 | +3.5% | +3.9% | -1.8% | |
| Q3 2019 | -3.8% | -3.8% | -1.6% | |
| Q2 2019 | -0.7% | -2.5% | +1.6% | |
| Q1 2019 | +5.2% | +5.3% | +2.6% | |
| Q4 2018 | -1.7% | -1.5% | -1.1% | |
| Q3 2018 | +4.4% | +3.6% | +4.9% | |
| Q2 2018 | +2.2% | +0.2% | +1.4% | |
| Q1 2018 | -2.6% | -3.5% | -5.2% | |
| Q4 2017 | -6.2% | -6.0% | -4.1% | |
| Q3 2017 | -1.6% | -1.9% | -4.0% | |
| Q2 2017 | -1.1% | +1.1% | +1.3% | |
| Q1 2017 | +0.7% | +1.9% | +4.5% | |
| Q4 2016 | +6.1% | +5.7% | +9.1% | |
| Q3 2016 | +4.4% | +6.7% | +7.0% | |
| Q2 2016 | -0.3% | -3.9% | -8.9% | |
| Q1 2016 | -3.2% | — | — | |
| Q4 2015 | -1.8% | — | — | |
| Q3 2015 | -2.2% | — | — | |
| Q2 2015 | +2.6% | — | — | |
| Q1 2015 | — | — | — | |
| Q3 2014 | — | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2014 | — | — | — | |
| Q3 2013 | — | — | — | |
| Q2 2013 | — | — | — | |
| Q1 2013 | — | — | — | |
| Q3 2012 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro